Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NYSE:MYOV NYSE:PBH NASDAQ:RVNC NASDAQ:VIE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.80-1.5%$8.07$5.20▼$10.67$1.21B1.161.40 million shs1.61 million shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsPBHPrestige Consumer Healthcare$76.33-1.6%$83.92$64.94▼$90.04$3.83B0.43311,351 shs507,395 shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.70 million shsN/AVIEViela Bio$53.01$53.01$25.02▼$65.00$2.91B0.431.07 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+6.44%+18.03%+9.57%+20.51%+62.36%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare-1.62%-3.04%-10.44%-5.62%+13.68%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+25.43%VIEViela Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.798 of 5 stars3.51.00.00.02.60.81.9MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare4.2534 of 5 stars2.34.00.03.52.91.71.9RVNCRevance Therapeutics2.8006 of 5 stars3.10.00.04.70.01.70.6VIEViela BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5030.68% UpsideMYOVMyovant Sciences 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3322.28% UpsideRVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideVIEViela Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RVNC, PBH, MYOV, VIE, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M5.06$0.30 per share28.95$2.68 per share3.28MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35PBHPrestige Consumer Healthcare$1.14B3.32$5.13 per share14.87$37.04 per share2.06RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11VIEViela Bio$50M58.26N/AN/A$7.14 per share7.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2831.4315.71N/A16.11%14.27%9.93%7/30/2025 (Estimated)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/APBHPrestige Consumer Healthcare$214.60M$4.2917.7916.042.3318.86%12.87%6.78%8/6/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)VIEViela Bio-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/ALatest RVNC, PBH, MYOV, VIE, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$64.27 millionN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/AVIEViela BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26MYOVMyovant SciencesN/A1.571.45PBHPrestige Consumer Healthcare0.554.202.82RVNCRevance TherapeuticsN/A4.123.05VIEViela BioN/A19.5119.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%MYOVMyovant Sciences30.62%PBHPrestige Consumer Healthcare99.95%RVNCRevance Therapeutics97.70%VIEViela Bio46.98%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%MYOVMyovant Sciences1.90%PBHPrestige Consumer Healthcare1.40%RVNCRevance Therapeutics5.10%VIEViela Bio31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionablePBHPrestige Consumer Healthcare54049.42 million48.72 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableVIEViela Bio16654.95 millionN/ANot OptionableRVNC, PBH, MYOV, VIE, and AUPH HeadlinesRecent News About These CompaniesBETDAQ app downloadDecember 30, 2024 | bwsmartcities.businessworld.inBdc vs punjab 2022December 30, 2024 | everythingexperiential.businessworld.inEKhelo India Khelo lucky 3 result todayDecember 30, 2024 | bweducation.businessworld.inB777 Win SooterDecember 30, 2024 | bwdisrupt.businessworld.inBTherapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of HurdlesOctober 23, 2024 | medscape.comMAnti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia GravisOctober 16, 2024 | msn.comDmitry Bivol: Biography, record, fights and moreOctober 10, 2024 | espn.comRGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-DollarOctober 9, 2024 | de.investing.comRoche takes on Alexion as FDA approves satralizumab in NMOSDSeptember 29, 2024 | pharmaphorum.comPREGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial OfficerSeptember 17, 2024 | finanznachrichten.deREGENXBIO ernennt Mitchell Chan zum neuen CFO in WachstumsphaseSeptember 17, 2024 | de.investing.comRegenxbio Names Mitchell Chan CFOSeptember 17, 2024 | markets.businessinsider.comAstraZeneca spins out biotech to focus on autoimmune candidatesAugust 27, 2024 | pharmaphorum.comPComplement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsightAugust 21, 2024 | prnewswire.co.ukPMinority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company’s Business AffairsAugust 21, 2024 | law.comLFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 19, 2024 | finance.yahoo.comLitigation Leaders: Adam Siegel of Freshfields on Four ‘Cs’ of the Firm’s Litigation PracticeAugust 19, 2024 | law.comL2024 Fire Awards: Meet this year's Ablaze honoreesAugust 16, 2024 | bizjournals.comAmgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity PipelineAugust 8, 2024 | biospace.comBNovel Drug Made of Gold Nanocrystals Appears Safe in Multiple SclerosisApril 22, 2024 | medpagetoday.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Defies Bears, Leads S&P 500 in 2025By Chris Markoch | June 16, 2025View Palantir Defies Bears, Leads S&P 500 in 2025Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesMarketBeat Week in Review – 06/16 - 06/20By MarketBeat Staff | June 21, 2025View MarketBeat Week in Review – 06/16 - 06/20MarketBeat Week in Review – 06/30 - 07/04By MarketBeat Staff | July 5, 2025View MarketBeat Week in Review – 06/30 - 07/04MarketBeat Week in Review – 06/09 - 06/13By MarketBeat Staff | June 14, 2025View MarketBeat Week in Review – 06/09 - 06/13RVNC, PBH, MYOV, VIE, and AUPH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.80 -0.13 (-1.46%) Closing price 04:00 PM EasternExtended Trading$8.80 -0.01 (-0.06%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Prestige Consumer Healthcare NYSE:PBH$76.33 -1.21 (-1.56%) Closing price 03:58 PM EasternExtended Trading$76.47 +0.14 (+0.18%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Viela Bio NASDAQ:VIEViela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
